SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-328938
Filing Date
2021-11-15
Accepted
2021-11-15 07:35:57
Documents
14
Period of Report
2021-11-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d235926d8k.htm   iXBRL 8-K 24475
2 EX-99.1 d235926dex991.htm EX-99.1 57426
6 GRAPHIC g235926snaap2.jpg GRAPHIC 4196
  Complete submission text file 0001193125-21-328938.txt   224956

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gmtx-20211115.xsd EX-101.SCH 2911
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gmtx-20211115_lab.xml EX-101.LAB 18889
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gmtx-20211115_pre.xml EX-101.PRE 11873
7 EXTRACTED XBRL INSTANCE DOCUMENT d235926d8k_htm.xml XML 3535
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Filer) CIK: 0001816736 (see all company filings)

IRS No.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39438 | Film No.: 211406356
SIC: 2834 Pharmaceutical Preparations